Related Experiment Videos
Chronic hepatitis B: current and future treatment options
Anastasia Rivkina1, Sergey Rybalov
1Arnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, New York, USA. arivkina@liu.edu
Insights
Hepatitis B is a serious global health threat. Effective management and prevention strategies, including new drug development, are crucial for controlling this viral infection and its severe complications like liver cancer.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Hepatitis B virus (HBV) infection is a significant global health concern, ranking as the ninth leading cause of mortality worldwide.
- HBV infection can progress to severe liver diseases, including cirrhosis and hepatocellular carcinoma, underscoring the need for effective prevention and treatment strategies.
Observation:
- Current Food and Drug Administration-approved pharmacotherapeutic agents for chronic hepatitis B include interferon-alpha-2b and lamivudine.
- Emerging therapeutic agents show promise for improved management, with ongoing research into drugs such as adefovir, entecavir, and emtricitabine.
- Novel treatment modalities, including therapeutic vaccines and immunomodulators like thymosin alpha-1, are under development.
Findings:
- The landscape of hepatitis B pharmacotherapy is expanding with numerous new agents demonstrating potential efficacy.
- Treatment strategies for hepatitis B infection in liver transplant recipients are also advancing, incorporating agents like hepatitis B immunoglobulin and nucleoside analogues.
Implications:
- Advancements in antiviral therapies and preventative measures are critical for reducing the global burden of hepatitis B and its sequelae.
- Further research and clinical trials are essential to fully evaluate the safety and efficacy of novel hepatitis B treatments.
Abstract:
Hepatitis B, a major viral infection that can lead to cirrhosis and hepatocellular carcinoma, is the ninth most common cause of death worldwide. Prevention of hepatitis B virus transmission is key to reducing the spread of this serious condition. Management of chronic hepatitis B requires significant knowledge of approved pharmacotherapeutic agents and their limitations. Today, agents approved by the Food and Drug Administration for this infection are interferon-alpha-2b and lamivudine. Newer agents are being developed and hold promise: adefovir, famciclovir, ganciclovir, lobucavir, entecavir, emtricitabine, L-deoxythymidine, clevudine, a therapeutic vaccine, and thymosin alpha-1. Therapeutic options for managing hepatitis infection after liver transplantation are also evolving. These include hepatitis B immunoglobulin and nucleoside analogues.